PITTSBURGH, June 9 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) todayannounced that its subsidiary, Genpharm ULC, has received final approval fromthe U.S. Food and Drug Administration (FDA) for its Abbreviated New DrugApplication (ANDA) for Zaleplon Capsules, 5 mg and 10 mg.

Zaleplon Capsules are the generic version of King Pharmaceuticals'Sonata(R) Capsules, which had U.S. sales of approximately $88 million for the12 months ending March 31, 2008, according to IMS Health.

This product is shipping immediately and will be sold under the MylanPharmaceuticals brand.

Mylan Inc., with a presence in more than 90 countries, ranks among theleading diversified generic and specialty pharmaceutical companies in theworld. The company maintains one of the industry's broadest -- and highestquality -- product portfolios, supported by a robust product pipeline; owns acontrolling interest in the world's second largest active pharmaceuticalingredient manufacturer; and operates a specialty business focused onrespiratory and allergy therapies.

SOURCE Mylan Inc.